世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 Liquid Embolic Agent Market Size, Share & Trends Analysis Report By Product Type (Ethylene Vinyl Alcohol Copolymer, Cyanoacrylates), By Application (Arteriovenous Malformations, Hypervascular Tumors), By End Use, By Region, And Segment Forecasts, 2025 - 2033
Liquid Embolic Agent Market Summary The global liquid embolic agent market size was estimated at USD 257.9 million in 2024 and is projected to reach USD 595.0 million by 2033, growing at a CAGR ... もっと見る
SummaryLiquid Embolic Agent Market SummaryThe global liquid embolic agent market size was estimated at USD 257.9 million in 2024 and is projected to reach USD 595.0 million by 2033, growing at a CAGR of 9.89% from 2025 to 2033. The liquid embolic agent industry is primarily driven by advancements in minimally invasive procedures and the increasing prevalence of vascular diseases worldwide. As healthcare systems shift towards less invasive techniques, the demand for embolization agents used in treating conditions like aneurysms, arteriovenous malformations (AVMs), and tumors has surged. The growing neurovascular and peripheral vascular abnormalities and diseases such as AVMs, dural arteriovenous fistulas (DAVFs), and hypervascular tumors, among others are primarily driving the market growth. According to a research article published by the National Center for Biotechnology Information, arteriovenous malformations (AVMs) are often asymptomatic in about 15% of cases until a clinical event occurs. Between 41% and 79% of AVMs are present with intracranial hemorrhage. They are the second most common cause of intracranial bleeding after cerebral aneurysms, accounting for approximately 10% of all subarachnoid hemorrhages. Children are more likely than adults to be present with hemorrhage. While hemorrhages are typically intraparenchymal, they can also primarily occur in the subarachnoid space. In addition, according to an article published by Radiopaedia.org in November 2024, the incidence of solitary AVM is 98% and multiple AVM is 2%. Thus, growing AVM cases are a primary contributor to market growth. Furthermore, according to an American Chemical Society report published in April 2021, brain aneurysms are abnormal dilations that primarily develop at the branch points of cerebral blood vessels. Over 60% of aneurysms are now managed using minimally invasive endovascular techniques, such as flow diversion or the permanent placement of metallic intrasaccular coils. However, these current devices have an unfavorable primary success rate in approximately 20-30% of cases, and the overall effectiveness varies significantly depending on the aneurysm’s type and location. Hence, this brings a growth opportunity for the liquid embolic agent industry during the forecast period. Neurovascular embolization is commonly performed using liquid embolic agents to treat conditions such as AVMs, DAVFs, and hypervascular tumors. Currently, commonly used liquid embolic agents include n-butyl cyanoacrylate (n-BCA) and ethylene vinyl alcohol copolymer (EVOH) based agents, such as Onyx (Medtronic), Squid (Balt), and PHIL (Terumo), a non-biodegradable iodine-based liquid embolic agent. Additionally, TRUFILL (CERENOVUS, Johnson & Johnson) has recently been introduced. For instance, in March 2024, CERENOVUS, a division of Johnson & Johnson MedTech, announced the launch of the TRUFILL n-BCA Liquid Embolic System Procedural Set. This new offer expands CERENOVUS’s hemorrhagic stroke portfolio by providing a comprehensive procedural set that includes two configuration options and all necessary accessories for preparing and delivering the TRUFILL n-BCA Liquid Embolic System. These agents are favored for their ability to effectively occlude abnormal vascular structures, providing minimally invasive treatment options with high precision. The choice of embolic agent depends on the specific clinical scenario and lesion characteristics, with ongoing innovations aiming to improve safety, handling, and long-term efficacy in neurointerventional procedures. Global Liquid Embolic Agent Market Report Segmentation This report forecasts revenue growth at the global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global liquid embolic agent market report based on product type, application, end use, and region: • Product Type Outlook (Revenue, USD Million, 2021 - 2033) • Ethylene Vinyl Alcohol Copolymer (EVOH) • Cyanoacrylates o N-BCA (n-Butyl Cyanoacrylate) o N-HCA (n-Hexyl Cyanoacrylate) • Others • Application Outlook (Revenue, USD Million, 2021 - 2033) • Arteriovenous Malformations (AVM) • Hypervascular Tumors • Peripheral Vasculature Hemorrhage • Others • End Use Outlook (Revenue, USD Million, 2021 - 2033) • Hospitals • Specialty Clinics • Ambulatory Surgical Centers (ASCs) • Others • Regional Outlook (Revenue, USD Million, 2021 - 2033) • North America o U.S. o Canada o Mexico • Europe o Germany o UK o France o Italy o Spain o Denmark o Sweden o Norway • Asia Pacific o Japan o China o India o South Korea o Australia o Thailand • Latin America o Brazil o Argentina • Middle East & Africa o South Africa o Saudi Arabia o UAE o Kuwait Table of ContentsTable of ContentsChapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.1.1. Product Type 1.1.2. Application 1.1.3. End-use 1.1.4. Regional scope 1.1.5. Estimates and forecast timeline 1.2. Research Methodology 1.3. Information Procurement 1.3.1. Purchased database 1.3.2. GVR’s internal database 1.3.3. Secondary sources 1.3.4. Primary research 1.3.5. Details of primary research 1.4. Information or Data Analysis 1.4.1. Data analysis models 1.5. Market Formulation & Validation 1.6. Model Details 1.6.1. Commodity flow analysis (Model 1) 1.6.1.1. Approach 1: Commodity flow approach 1.6.2. Volume price analysis (Model 2) 1.6.2.1. Approach 2: Volume price analysis 1.7. List of Secondary Sources 1.8. List of Primary Sources 1.9. Objectives 1.9.1. Objective 1 1.9.2. Objective 2 Chapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.3. Competitive Insights Chapter 3. Liquid Embolic Agent Market Variables, Trends, & Scope 3.1. Market Lineage Outlook 3.2. Market Dynamics 3.2.1. Market Driver Analysis 3.2.1.1. Rising Prevalence of Vascular Diseases 3.2.1.2. Advancements in Embolization Technologies 3.2.1.3. Growing Preference for Minimally Invasive Procedures 3.2.2. Market Restraint Analysis 3.2.2.1. High cost of agents and materials 3.2.2.2. Risk of complications and adverse events 3.2.2.3. Availability of alternative treatments 3.2.3. Market Opportunities Analysis 3.2.3.1. Technological innovations 3.2.3.2. Growing number of clinical trials 3.2.3.3. Expanding application areas 3.2.4. Market Challenge Analysis 3.2.4.1. Regulatory and approval barriers 3.3. Liquid Embolic Agent Market Analysis Tools 3.3.1. Industry Analysis - Porter’s 3.3.1.1. Bargaining power of suppliers 3.3.1.2. Bargaining power of buyers 3.3.1.3. Threat of substitutes 3.3.1.4. Threat of new entrants 3.3.1.5. Competitive rivalry 3.3.2. PESTEL Analysis 3.3.2.1. Political & Legal Landscape 3.3.2.2. Economic and Social Landscape 3.3.2.3. Technological landscape Chapter 4. Liquid Embolic Agent Market: Product Type Estimates & Trend Analysis 4.1. Segment Dashboard 4.2. Global Liquid Embolic Agent Market Movement Analysis 4.3. Global Liquid Embolic Agent Market Size & Trend Analysis, by Product Type, 2021 to 2033 (USD Million) 4.4. Ethylene Vinyl Alcohol Copolymer (EVOH) 4.4.1. Ethylene Vinyl Alcohol Copolymer (EVOH) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) 4.5. Cyanoacrylates 4.5.1. Cyanoacrylates Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) 4.5.1.1. N-BCA (n-Butyl Cyanoacrylate) 4.5.1.1.1. N-BCA (n-Butyl Cyanoacrylate) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) 4.5.1.2. N-HCA (n-Hexyl Cyanoacrylate) 4.5.1.2.1. N-HCA (n-Hexyl Cyanoacrylate) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) 4.6. Others 4.6.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) Chapter 5. Liquid Embolic Agent Market: Application Estimates & Trend Analysis 5.1. Segment Dashboard 5.2. Global Liquid Embolic Agent Market Movement Analysis 5.3. Global Liquid Embolic Agent Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million) 5.4. Arteriovenous Malformations (AVM) 5.4.1. Arteriovenous Malformations (AVM) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) 5.5. Hypervascular Tumors 5.5.1. Hypervascular Tumors Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) 5.6. Peripheral Vasculature Hemorrhage 5.6.1. Peripheral Vasculature Hemorrhage Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) 5.7. Others 5.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) Chapter 6. Liquid Embolic Agent Market: End Use Estimates & Trend Analysis 6.1. Segment Dashboard 6.2. Global Liquid Embolic Agent Market Movement Analysis 6.3. Global Liquid Embolic Agent Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million) 6.4. Hospitals 6.4.1. Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) 6.5. Specialty Clinics 6.5.1. Specialty Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) 6.6. Ambulatory Surgical Centers (ASCs) 6.6.1. Ambulatory Surgical Centers (ASCs) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) 6.7. Others 6.7.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) Chapter 7. Liquid Embolic Agent Market: Regional Estimates & Trend Analysis By Product Type, By Application, By End Use 7.1. Regional Dashboard 7.2. Market Size & Forecasts and Trend Analysis, 2021 to 2033 7.3. North America 7.3.1. North America Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.3.2. U.S. 7.3.2.1. Key Country Dynamics 7.3.2.2. Competitive Scenario 7.3.2.3. Regulatory Scenario 7.3.2.4. Reimbursement Scenario 7.3.2.5. U.S. Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.3.3. Canada 7.3.3.1. Key Country Dynamics 7.3.3.2. Competitive Scenario 7.3.3.3. Regulatory Scenario 7.3.3.4. Reimbursement Scenario 7.3.3.5. Canada Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.3.4. Mexico 7.3.4.1. Key Country Dynamics 7.3.4.2. Competitive Scenario 7.3.4.3. Regulatory Scenario 7.3.4.4. Reimbursement Scenario 7.3.4.5. Mexico Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.4. Europe 7.4.1. Europe Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.4.2. UK 7.4.2.1. Key Country Dynamics 7.4.2.2. Competitive Scenario 7.4.2.3. Regulatory Scenario 7.4.2.4. Reimbursement Scenario 7.4.2.5. UK Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.4.3. Germany 7.4.3.1. Key Country Dynamics 7.4.3.2. Competitive Scenario 7.4.3.3. Regulatory Scenario 7.4.3.4. Reimbursement Scenario 7.4.3.5. Germany Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.4.4. France 7.4.4.1. Key Country Dynamics 7.4.4.2. Competitive Scenario 7.4.4.3. Regulatory Scenario 7.4.4.4. Reimbursement Scenario 7.4.4.5. France Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.4.5. Italy 7.4.5.1. Key Country Dynamics 7.4.5.2. Competitive Scenario 7.4.5.3. Regulatory Scenario 7.4.5.4. Reimbursement Scenario 7.4.5.5. Italy Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.4.6. Spain 7.4.6.1. Key Country Dynamics 7.4.6.2. Competitive Scenario 7.4.6.3. Regulatory Scenario 7.4.6.4. Reimbursement Scenario 7.4.6.5. Spain Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.4.7. Denmark 7.4.7.1. Key Country Dynamics 7.4.7.2. Competitive Scenario 7.4.7.3. Regulatory Scenario 7.4.7.4. Reimbursement Scenario 7.4.7.5. Denmark Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.4.8. Sweden 7.4.8.1. Key Country Dynamics 7.4.8.2. Competitive Scenario 7.4.8.3. Regulatory Scenario 7.4.8.4. Reimbursement Scenario 7.4.8.5. Sweden Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.4.9. Norway 7.4.9.1. Key Country Dynamics 7.4.9.2. Competitive Scenario 7.4.9.3. Regulatory Scenario 7.4.9.4. Reimbursement Scenario 7.4.9.5. Norway Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.5. Asia Pacific 7.5.1. Asia Pacific Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.5.2. Japan 7.5.2.1. Key Country Dynamics 7.5.2.2. Competitive Scenario 7.5.2.3. Regulatory Scenario 7.5.2.4. Reimbursement Scenario 7.5.2.5. Japan Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.5.3. China 7.5.3.1. Key Country Dynamics 7.5.3.2. Competitive Scenario 7.5.3.3. Regulatory Scenario 7.5.3.4. Reimbursement Scenario 7.5.3.5. China Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.5.4. India 7.5.4.1. Key Country Dynamics 7.5.4.2. Competitive Scenario 7.5.4.3. Regulatory Scenario 7.5.4.4. Reimbursement Scenario 7.5.4.5. India Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.5.5. South Korea 7.5.5.1. Key Country Dynamics 7.5.5.2. Competitive Scenario 7.5.5.3. Regulatory Scenario 7.5.5.4. Reimbursement Scenario 7.5.5.5. South Korea Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.5.6. Australia 7.5.6.1. Key Country Dynamics 7.5.6.2. Competitive Scenario 7.5.6.3. Regulatory Scenario 7.5.6.4. Reimbursement Scenario 7.5.6.5. Australia Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.5.7. Thailand 7.5.7.1. Key Country Dynamics 7.5.7.2. Competitive Scenario 7.5.7.3. Regulatory Scenario 7.5.7.4. Reimbursement Scenario 7.5.7.5. Thailand Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.6. Latin America 7.6.1. Latin America Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.6.2. Brazil 7.6.2.1. Key Country Dynamics 7.6.2.2. Competitive Scenario 7.6.2.3. Regulatory Scenario 7.6.2.4. Reimbursement Scenario 7.6.2.5. Brazil Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.6.3. Argentina 7.6.3.1. Key Country Dynamics 7.6.3.2. Competitive Scenario 7.6.3.3. Regulatory Scenario 7.6.3.4. Reimbursement Scenario 7.6.3.5. Argentina Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.7. Middle East & Africa 7.7.1. Middle East & Africa Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.7.2. South Africa 7.7.2.1. Key Country Dynamics 7.7.2.2. Competitive Scenario 7.7.2.3. Regulatory Scenario 7.7.2.4. Reimbursement Scenario 7.7.2.5. South Africa Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.7.3. Saudi Arabia 7.7.3.1. Key Country Dynamics 7.7.3.2. Competitive Scenario 7.7.3.3. Regulatory Scenario 7.7.3.4. Reimbursement Scenario 7.7.3.5. Saudi Arabia Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.7.4. UAE 7.7.4.1. Key Country Dynamics 7.7.4.2. Competitive Scenario 7.7.4.3. Regulatory Scenario 7.7.4.4. Reimbursement Scenario 7.7.4.5. UAE Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) 7.7.5. Kuwait 7.7.5.1. Key Country Dynamics 7.7.5.2. Competitive Scenario 7.7.5.3. Regulatory Scenario 7.7.5.4. Reimbursement Scenario 7.7.5.5. Kuwait Liquid Embolic Agent Market Estimates and Forecasts, 2021 - 2033 (USD Million) Chapter 8. Competitive Landscape 8.1. Recent Developments & Impact Analysis, By Key Market Participants 8.2. Company/Competition Categorization 8.2.1. Innovators 8.3. Vendor Landscape 8.3.1. List of key distributors and channel partners 8.3.2. Key customers 8.3.3. Global Key company market share analysis, 2024 8.3.4. Johnson & Johnson 8.3.4.1. Company Overview 8.3.4.2. Financial Performance 8.3.4.3. Service Benchmarking 8.3.4.4. Strategic Initiatives 8.3.5. Medtronic 8.3.5.1. Company Overview 8.3.5.2. Financial Performance 8.3.5.3. Service Benchmarking 8.3.5.4. Strategic Initiatives 8.3.6. B. Braun SE 8.3.6.1. Company Overview 8.3.6.2. Financial Performance 8.3.6.3. Product Benchmarking 8.3.6.4. Strategic Initiatives 8.3.7. Terumo 8.3.7.1. Company Overview 8.3.7.2. Financial Performance 8.3.7.3. Product Benchmarking 8.3.7.4. Strategic Initiatives 8.3.8. Boston Scientific Corporation 8.3.8.1. Company Overview 8.3.8.2. Financial Performance 8.3.8.3. Product Benchmarking 8.3.8.4. Strategic Initiatives 8.3.9. Balt 8.3.9.1. Company Overview 8.3.9.2. Financial Performance 8.3.9.3. Product Benchmarking 8.3.9.4. Strategic Initiatives 8.3.10. BlackSwan Vascular, Inc. 8.3.10.1. Company Overview 8.3.10.2. Financial Performance 8.3.10.3. Product Benchmarking 8.3.10.4. Strategic Initiatives 8.3.11. INVAMED 8.3.11.1. Company Overview 8.3.11.2. Financial Performance 8.3.11.3. Product Benchmarking 8.3.11.4. Strategic Initiatives 8.3.12. Meril 8.3.12.1. Company Overview 8.3.12.2. Financial Performance 8.3.12.3. Product Benchmarking 8.3.12.4. Strategic Initiatives 8.3.13. Gem srl 8.3.13.1. Company Overview 8.3.13.2. Financial Performance 8.3.13.3. Product Benchmarking 8.3.13.4. Strategic Initiatives 8.4. Heat Map Analysis/ Company Market Position Analysis 8.5. Estimated Company Market Share Analysis, 2024 8.6. List of Other Key Market Players
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療機器）の最新刊レポート
Grand View Research社の 医療機器分野 での最新刊レポート
本レポートと同じKEY WORD（ethylene）の最新刊レポート
よくあるご質問Grand View Research社はどのような調査会社ですか?グランドビューリサーチ（Grand View Research）は通信技術、化学品、材料、ヘルスケア、エネルギーなど広範な市場を対象にした調査報告書を出版しています。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
